We read Lee and colleagues' systematic review on geriatric assessments (GA) in cancer
clinical trials [
[1]
] with great interest. This study provides a comprehensive review of how the GA has
been adopted and adapted for use in existing cancer clinical trials. We wish to discuss
gaps and next steps on topics highlighted by Lee et al. using recent solutions proposed
during the 2021 National Academies of Sciences, Engineering, and Medicine (NASEM)
workshop on improving the evidence base for older adults with cancer which brought
together geriatric oncology experts from within and across the clinical research and
regulatory strata (see Table 1).Table 1NASEM improving the evidence base for treatment decision making for older adults with
cancer virtual workshop 2021 adapted recommendations.
|
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Geriatric OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Use of geriatric assessment in cancer clinical trials: a systematic review.J Geriatr Oncol. 2022; 13: 20220509https://doi.org/10.1016/j.jgo.2022.04.014
- Cisplatin eligibility issues and alternative regimens in locoregionally advanced head and neck cancer: recommendations for clinical practice.Front Oncol. 2019; 9: 20190611https://doi.org/10.3389/fonc.2019.00464
- COMOGRAM.http://comogram.org(accessed September 24th, 2022)Date: 2019
- Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for elderly or frail elderly patients with met.Colorectal Cancer. 2018;
- Atezolizumab after chemo-radiotherapy for MIBC patients not eligible for radical cystectomy.
- Thoracic radiotherapy plus durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy.
- Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology.J Clin Oncol. 2018; 36: 20180521https://doi.org/10.1200/jco.2018.78.8687
- Change in four measures of physical function among older adults during lung cancer treatment: a mixed methods cohort study.J Geriatr Oncol. 2022; : 20220901https://doi.org/10.1016/j.jgo.2022.08.015
- Using the outcome prioritization tool (OPT) to assess the preferences of older patients in clinical decision-making: a review.Maturitas. 2019; 128: 20190730https://doi.org/10.1016/j.maturitas.2019.07.022
- An exploratory analysis of the “was it worth it?” questionnaire as a novel metric to capture patient perceptions of cancer treatment.Value Health. 2022; 25: 1081-1086https://doi.org/10.1016/j.jval.2021.11.1368
- The time toxicity of cancer treatment.J Clin Oncol. 2022; 40: 1611-1615https://doi.org/10.1200/jco.21.02810
- Multidisciplinary development of the geriatric core dataset for clinical research in older patients with cancer: a French initiative with international survey.Eur J Cancer. 2018; 103: 20180911https://doi.org/10.1016/j.ejca.2018.07.137
- Integrating geriatric assessment into routine gastrointestinal (GI) consultation: the cancer and aging resilience evaluation (CARE).J Geriatr Oncol. 2020; 11 (2019/04/22)https://doi.org/10.1016/j.jgo.2019.04.008
- Introducing the v-RFA, a voice assistant-based geriatric assessment.J Geriatr Oncol. 2022; : 20220511https://doi.org/10.1016/j.jgo.2022.05.001
- A collective intelligence platform to support older cancer survivors: Towards the definition of LifeChamps system and big data reference architecture.in: MEDINFO 2021: One world, one health–global partnership for digital innovation. IOS Press, 2022: 1008-1009
Article Info
Publication History
Published online: October 29, 2022
Accepted:
October 20,
2022
Received:
October 16,
2022
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2022 Elsevier Ltd. All rights reserved.
